Therapeutic effects of imatinib and selective PDGF receptor inhibitor in a mouse model of systemic sclerosis

我们评估了伊马替尼对系统性硬化症小鼠模型的治疗效果。与对照组相比，伊马替尼处理的紧皮（Tsk）小鼠的真皮增厚减少（186.40±20.35 vs 101.96±16.64 μm，p <0.01）。此外，伊马替尼治疗的小鼠皮肤纤维连接蛋白、TGF-β和I型胶原mRNA表达显著降低（I型胶原：-38% ;纤维连接蛋白：-46% ; TGF-β：-26%）。此外，与媒介物治疗相比，伊马替尼治疗还显著降低血清抗Scl 70抗体水平（0.83±0.23对0.38 ±0.05，p <0.05）。结论：伊马替尼对Tsk小鼠有治疗作用。这项研究的结果表明，伊马替尼可能是一种新的方法治疗系统性硬化症。

We evaluated the therapeutic effects of imatinib on a mouse model of systemic sclerosis. Compared to controls, imatinib-treated tight skin (Tsk) mice had reduced dermal thickening(186.40±20.35 vs 101.96±16.64 μm, p <0.01). Furthermore, imatinib-treated mice had significantly reduced skin fibronectin, TGF-b and collagen type I mRNA expressions(collagen type I : -38% ; fibronectin:-46% ; TGF-β : -26%). In addition, imatinib treatment also significantly reduced the serum anti-Scl70 antibody levels compared to vehicle treatment(0.83±0.23 vs 0.38 ±0.05, p <0.05). Conclusion: Imatinib treatment showed therapeutic effects in Tsk mice. The results of this study suggest that imatinib may be a novel approach for treating systemic sclerosis.